Trial Profile
A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Therapeutic Use
- Acronyms NF105-CABO
- 02 May 2023 Status changed from active, no longer recruiting to completed.
- 13 Jan 2023 Planned primary completion date changed from 1 Dec 2023 to 6 Feb 2023.
- 12 Jan 2023 Planned End Date changed from 1 Dec 2023 to 6 Feb 2023.